Neurology Medical News about Drug Costs

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective
Value in Health, 11/04/09

Garrison LP et al. – The authors key recommendation is that current CEA practice acknowledge and embrace this limitation by adopting a new standard for the reference case as one of a "limited societal" or "health systems" perspective, using acquisition drug prices while including indirect costs and community preferences. The field of pharmacoeconomics also needs to acknowledge the limitations of this perspective when it comes to important questions of research and development costs, and incentives for innovation.

<< Previous
Perineural infusion of 0.5% ropivacaine for successful treatment...

Next >>
Effect of glatiramer acetate on conversion to clinically definite...

Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations
Value in Health, 11/11/09 Relevance Score: 71%

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report-Part III
Value in Health, 10/29/09 Relevance Score: 71%

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report-Part VI
Value in Health, 10/29/09 Relevance Score: 71%

Value-Based Insurance Design in Medicare
Applied Health Economics and Health Policy, 10/20/09 Relevance Score: 70%

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report-Part IV
Value in Health, 10/19/09 Relevance Score: 69%